Kevin Kalinsky, MD, MS, FASCO

Division Director of Medical Oncology at Winship/Director Glenn Family Breast Center/Opinions=my own

[Annals of Oncology @Annals_Oncology]

📢 #ESMO26 concomitant paper: OS from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs pbo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy.
🔗https://t.co/MZRmGK0zc2
@KalinskyKevin @BianchiniGP

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Coming up this week! Join us Sept. 19 for the Atlanta Breast Cancer Conference, co-chaired by Winship experts Kevin Kalinsky, MD, MS; Tari King, MD; and Reshma Jagsi, MD, DPhil.

There’s still time to register! Learn more ➡️ https://t.co/PH6a337YHc

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

Team effort! @SWOG @WinshipAtEmory

[Annals of Oncology @Annals_Oncology]

🆕article in press: Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) @KalinskyKevin

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

Looking forward to this meeting!

[Research To Practice @DrNeilLove]

Our 5th Annual National General Medical Oncology Summit will be a one-of-a-kind offering, featuring a multidisciplinary faculty of clinical investigators and a blend of short presentations, lively moderated panel discussions and dedicated Q&A. Register: https://t.co/ETAElSudRf

[ECOG-ACRIN Cancer Research Group @eaonc]

.@eaonc is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.

📅Feb 4 | 4 PM ET
🎙 @jsparano, @KalinskyKevin, @RimapatelMD
🔗https://t.co/tRepTjth6n

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

Join me at the 43rd Annual Miami Breast Cancer Conference! I'll be sharing insights alongside top experts to advance breast cancer care. Use my last name discount code for FREE registration. Register today: https://t.co/0aEfUEWmeH #MBCC25 #BreastCancerCare #BCSM

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA1241 is evaluating tissue samples from past TAILORx & RxPONDER trial participants who experienced a recurrence. This research aims to uncover why #BreastCancer returns after treatment. https://t.co/IrRNFtQ6GS cc: @jsparano, @KalinskyKevin, @RimapatelMD

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA1241 is evaluating tissue samples from past TAILORx & RxPONDER trial participants who experienced a recurrence. This research aims to uncover why #BreastCancer returns after treatment. https://t.co/IrRNFtQ6GS cc: @jsparano, @KalinskyKevin, @RimapatelMD

[Oncology Brothers @OncBrothers]

From #ASH —> #SABCS25! Look forward to seeing how this is going to change/inform our practice in breast cancer!!

In Person: Dec 10, 2025
⏰ Time: 7-9PM
✅ Register here: https://t.co/Zj8usjTg1o

#OncTwitter #MedTwitter #bcsm #AdvInOnc25 @OncUpdates @OncoAlert

[ECOG-ACRIN Cancer Research Group @eaonc]

Trial Activation: EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. For more information: https://t.co/IrRNFtQ6GS cc: @KalinskyKevin, @RimapatelMD

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

@jhaveri_komal Totally agree! And back at you @jhaveri_komal

[Eleonora Teplinsky, MD, FASCO @drteplinsky]

Getting ready for @OncLive #BTGBreast25 tomorrow. Let's do some polling questions! #MJHLifeSciences @jhaveri_komal @KalinskyKevin @Neil_Iyengar @JAMouabbi

When considering de-escalation in HER2+ early breast cancer, which factor most influences your decision?

[Eleonora Teplinsky, MD, FASCO @drteplinsky]

Getting ready for @OncLive #BTGBreast25 tomorrow. Let's do some polling questions! #MJHLifeSciences @jhaveri_komal @KalinskyKevin @Neil_Iyengar @JAMouabbi

Are TIL levels currently influencing your treatment decisions in #TNBC in clinical practice? #breastcancer

[Research To Practice @DrNeilLove]

In this episode of 5-Minute Journal Club, Dr Neil Love is joined by Dr Kevin Kalinsky to define the future role of TROP2-directed antibody-drug conjugates in breast cancer. Watch or listen here: https://t.co/9N75ZSOmCm

[BioAscend @BioAscend]

We kick-off the inaugural Atlanta Breast Cancer Conference with @KalinskyKevin welcoming attendees to discuss the care of multiple breast cancer subtypes.

#AtlBreast25

[Nabil Saba, MD @DrNabilSaba]

Still time to register! Join our esteemmed faculty ⁦@EmoryUniversity ⁦@WinshipAtEmory⁩ Updates in #HNCA https://t.co/3LZShVVcGk on September 6th; ⁦@StokedStokes⁩ ⁦@NikkiSchmittMD⁩ ⁦@ConorSteuerMD⁩

[Neil Iyengar, MD @Neil_Iyengar]

Absolutely outstanding breast cancer session at #DDHO2025. Major themes included treatment de-escalation strategies, adjuvant advances making cure even more possible, and of course lifestyle guidance. I am so incredibly excited to join the remarkable team at @WinshipAtEmory

[Georgia Society of Clinical Oncology @Gasco_Oncology]

The Glenn Family Breast Cancer Center invites you to the Inaugural Atlanta Breast Cancer Conference on Saturday, September 27, 2025. Learn more and register at https://t.co/qm4Ko6JBa8
#ATLBreast25

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

@Dr_RShatsky @UCSDHealthSci @UCSDCancer Congrats!!!

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

@Neil_Iyengar @WinshipAtEmory We are so excited!!!